RESTASIS® Patient Education Materials
Please fill out and submit the form below to download materials electronically.
PDF Forms to Download
The following materials will be available to download after you have finished filling out the form above and clicked the "submit" button.
- Chronic Dry Eye and RESTASIS®
- Educational brochure providing patients with useful information about Chronic Dry Eye and treatment with RESTASIS® Ophthalmic Emulsion.
- OSDI© Questionnaire
- Complete, easy-to-use format for Ocular Surface Dryness Index© Questionnaire, a useful tool for discussing and diagnosing Chronic Dry Eye.
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.